Stephen Bruso joined the Morningside investment team in 2019 and focuses on investments in both the biopharma and digital health fields.
He has extensive experience providing operational and management oversight to early-stage companies. Mr. Bruso serves as a director for numerous private companies including Cognito Therapeutics, Curai, Suvera, Vesigen Therapeutics, Neuroelectrics, Innodem Neurosciences, Manistee Therapeutics, MedRhythms, Huckleberry, Ieso Digital Health, Wellinks, and DeepCure; he is a board observer at Linus Health.
Prior to joining Morningside, Mr. Bruso worked at a series of molecular diagnostics startups spun out from the Church Lab at HMS before co-leading the development and launch of cloud software products at an e-commerce startup. He received his MBA from Boston University in 2019, graduating magna cum laude. He received hisBA from Emory University in 2009.
The Board and Leadership Team
Group Chief Science & Strategy Officer
Chief Operating Officer (UK)
SVP US Market Development
Chief Artificial Intelligence Officer
Interim Chief Product Officer
EVP Impact & Corporate Development
EVP Legal & IP